8-K: Precipio Inc. Reports Record Q2 Revenue, Positive Adjusted EBITDA

Precipio, Inc. announced its second quarter 2026 financial results, highlighting record quarterly revenue of $7.0 million and a return to positive Adjusted EBITDA of $0.4 million.

Summary

• Precipio, Inc. reported its financial results for the second quarter ended June 30, 2026.
• Revenue reached a quarterly record of $7.0 million, an increase from $6.7 million in Q1-2026 and a 22% year-over-year increase from $5.7 million in Q2-2025.
• Pathology revenue was $6.1 million, and product revenue was $0.9 million.
• Adjusted EBITDA was positive at $0.4 million, a significant improvement from $(0.2) million in Q1-2026.
• Cash flow from operations was $0.7 million, and the total increase in cash was $0.5 million, resulting in an end-of-quarter cash balance exceeding $3 million.
• The company achieved this cash position without a financing event.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with the company achieving record revenue and returning to positive Adjusted EBITDA, indicating improving operational performance and financial health.

Positives

• Achieved record quarterly revenue of $7.0 million.
• Returned to positive Adjusted EBITDA of $0.4 million, up from $(0.2) million in Q1-2026.
• Generated $0.7 million in cash flow from operations.
• Increased total cash balance to over $3 million, a $0.5 million increase in the quarter.
• Product revenues increased 21% from the previous high in Q4-2025.
• Demonstrated operational strength by increasing cash without a financing event.

Negatives

• Net income/(loss) for Q2-2026 was $(0.2) million, compared to a net income of $0.1 million in Q2-2025.

Risks

• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that could cause actual results to differ materially from those projected.
• These risks are discussed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and other SEC filings.

Future Outlook

The company is encouraged by its progress and believes it is well-positioned to continue building on its momentum. Further discussion on Q2-2026 performance and outlook will be provided on the August 17th shareholder call.

Management Comments

• "As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history."
• "Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M."
• "We've achieved this level of cash without a financing event, demonstrating the strength of our operations."
• "We're encouraged by the progress we've made and believe we are well positioned to continue building on this momentum."

Industry Context

StockSavvy.ai notes that Precipio's focus on specialty cancer diagnostics addresses a critical need in the healthcare sector. The reported revenue growth and return to positive Adjusted EBITDA align with a trend of improving operational efficiency and financial recovery seen in some specialized diagnostic companies, particularly those demonstrating strong product adoption and effective cost management.

Stakeholder Impact

• Shareholders: Positive impact from record revenue, positive Adjusted EBITDA, and strengthening cash position, suggesting improved financial health and operational performance.
• Employees: Continued operational success may lead to greater job security and potential for future growth.
• Customers: Improved product revenue and diagnostic capabilities may lead to better services and outcomes.
• Creditors: Strengthening cash position and positive EBITDA improve the company's ability to meet its financial obligations.

Next Steps

• Provide additional information and a more in-depth discussion on Q2-2026 performance during the shareholder call on August 17th, 2026.
• Continue to build on operational momentum.

Key Dates

Recommendation

The filing shows significant operational improvements with record revenue and a return to positive Adjusted EBITDA, which are strong positive indicators. However, the company still reported a GAAP net loss, and the forward-looking statements carry inherent risks. While the momentum is encouraging, a 'hold' recommendation is prudent pending sustained performance and further clarity on long-term profitability and growth drivers.

Keywords

cancer diagnostics, pathology revenue, product revenue, Adjusted EBITDA, cash flow, financial results, healthcare biotechnology